Literature DB >> 26627015

UV-Associated Mutations Underlie the Etiology of MCV-Negative Merkel Cell Carcinomas.

Stephen Q Wong1, Kelly Waldeck1, Ismael A Vergara1, Jan Schröder2, Jason Madore3, James S Wilmott3, Andrew J Colebatch4, Ricardo De Paoli-Iseppi3, Jason Li1, Richard Lupat1, Timothy Semple1, Gisela Mir Arnau1, Andrew Fellowes1, J Helen Leonard5, George Hruby3, Graham J Mann3, John F Thompson3, Carleen Cullinane1, Meredith Johnston1, Mark Shackleton6, Shahneen Sandhu6, David D L Bowtell7, Ricky W Johnstone6, Stephen B Fox7, Grant A McArthur6, Anthony T Papenfuss8, Richard A Scolyer3, Anthony J Gill9, Rodney J Hicks6, Richard W Tothill10.   

Abstract

Merkel cell carcinoma (MCC) is an uncommon, but highly malignant, cutaneous tumor. Merkel cell polyoma virus (MCV) has been implicated in a majority of MCC tumors; however, viral-negative tumors have been reported to be more prevalent in some geographic regions subject to high sun exposure. While the impact of MCV and viral T-antigens on MCC development has been extensively investigated, little is known about the etiology of viral-negative tumors. We performed targeted capture and massively parallel DNA sequencing of 619 cancer genes to compare the gene mutations and copy number alterations in MCV-positive (n = 13) and -negative (n = 21) MCC tumors and cell lines. We found that MCV-positive tumors displayed very low mutation rates, but MCV-negative tumors exhibited a high mutation burden associated with a UV-induced DNA damage signature. All viral-negative tumors harbored mutations in RB1, TP53, and a high frequency of mutations in NOTCH1 and FAT1. Additional mutated or amplified cancer genes of potential clinical importance included PI3K (PIK3CA, AKT1, PIK3CG) and MAPK (HRAS, NF1) pathway members and the receptor tyrosine kinase FGFR2. Furthermore, looking ahead to potential therapeutic strategies encompassing immune checkpoint inhibitors such as anti-PD-L1, we also assessed the status of T-cell-infiltrating lymphocytes (TIL) and PD-L1 in MCC tumors. A subset of viral-negative tumors exhibited high TILs and PD-L1 expression, corresponding with the higher mutation load within these cancers. Taken together, this study provides new insights into the underlying biology of viral-negative MCC and paves the road for further investigation into new treatment opportunities. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2015        PMID: 26627015     DOI: 10.1158/0008-5472.CAN-15-1877

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  111 in total

Review 1.  Recent Therapeutic Advances and Change in Treatment Paradigm of Patients with Merkel Cell Carcinoma.

Authors:  Rocio Garcia-Carbonero; Ivan Marquez-Rodas; Luis de la Cruz-Merino; Javier Martinez-Trufero; Miguel Angel Cabrera; Jose Maria Piulats; Jaume Capdevila; Enrique Grande; Salvador Martin-Algarra; Alfonso Berrocal
Journal:  Oncologist       Date:  2019-04-08

2.  Molecular Profiling of Multiple Primary Merkel Cell Carcinoma to Distinguish Genetically Distinct Tumors From Clonally Related Metastases.

Authors:  Kelly L Harms; Lorena Lazo de la Vega; Daniel H Hovelson; Samantha Rahrig; Andi K Cani; Chia-Jen Liu; Douglas R Fullen; Min Wang; Aleodor A Andea; Christopher K Bichakjian; Timothy M Johnson; Scott A Tomlins; Paul W Harms
Journal:  JAMA Dermatol       Date:  2017-06-01       Impact factor: 10.282

3.  MGMT promoter methylation status in Merkel cell carcinoma: in vitro versus invivo.

Authors:  Giuseppina Improta; Cathrin Ritter; Angela Pettinato; Valeria Vasta; David Schrama; Filippo Fraggetta; Jürgen C Becker
Journal:  J Cancer Res Clin Oncol       Date:  2017-04-12       Impact factor: 4.553

4.  B7-H3 Expression in Merkel Cell Carcinoma-Associated Endothelial Cells Correlates with Locally Aggressive Primary Tumor Features and Increased Vascular Density.

Authors:  Phyu P Aung; Edwin Roger Parra; Souptik Barua; Dawen Sui; Jing Ning; Barbara Mino; Debora Alejandra Ledesma; Jonathan L Curry; Priyadharsini Nagarajan; Carlos A Torres-Cabala; Eleni Efstathiou; Anh G Hoang; Michael K Wong; Jennifer A Wargo; Alexander J Lazar; Arvind Rao; Victor G Prieto; Ignacio Wistuba; Michael T Tetzlaff
Journal:  Clin Cancer Res       Date:  2019-02-26       Impact factor: 12.531

Review 5.  [Merkel cell carcinoma: cutaneous manifestation of a highly malignant pre-/pro-B cell neoplasia? : Novel concept about the cellular origin of Merkel cell carcinoma].

Authors:  C M Sauer; E Chteinberg; D Rennspiess; A K Kurz; A Zur Hausen
Journal:  Hautarzt       Date:  2017-03       Impact factor: 0.751

Review 6.  Merkel Cell Carcinoma in the Age of Immunotherapy: Facts and Hopes.

Authors:  Aric Colunga; Thomas Pulliam; Paul Nghiem
Journal:  Clin Cancer Res       Date:  2017-12-07       Impact factor: 12.531

Review 7.  Update on Merkel Cell Carcinoma.

Authors:  Michael T Tetzlaff; Priyadharsini Nagarajan
Journal:  Head Neck Pathol       Date:  2018-03-20

Review 8.  Treatment of Advanced Merkel Cell Carcinoma: Current Therapeutic Options and Novel Immunotherapy Approaches.

Authors:  Daniela Femia; Natalie Prinzi; Andrea Anichini; Roberta Mortarini; Federico Nichetti; Francesca Corti; Martina Torchio; Giorgia Peverelli; Filippo Pagani; Andrea Maurichi; Ilaria Mattavelli; Massimo Milione; Nice Bedini; Ambra Corti; Maria Di Bartolomeo; Filippo de Braud; Sara Pusceddu
Journal:  Target Oncol       Date:  2018-10       Impact factor: 4.493

9.  Prognostic relevance of high atonal homolog-1 expression in Merkel cell carcinoma.

Authors:  T Gambichler; S Mohtezebsade; U Wieland; S Silling; A-K Höh; M Dreißigacker; J Schaller; H-J Schulze; F Oellig; A Kreuter; E Stockfleth; M Stücker; F G Bechara; J C Becker
Journal:  J Cancer Res Clin Oncol       Date:  2016-09-13       Impact factor: 4.553

Review 10.  Proceedings of the NASHNP Companion Meeting, March 18th, 2018, Vancouver, BC, Canada: Salivary Neuroendocrine Carcinoma-An Overview of a Rare Disease with an Emphasis on Determining Tumor Origin.

Authors:  Rebecca D Chernock; Eric J Duncavage
Journal:  Head Neck Pathol       Date:  2018-03-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.